# Rubedo Life Sciences

develops selective senolytics using its AI-driven ALEMBIC platform; its lead candidate RLS-1496, a topical GPX4 modulator, reported positive preliminary Phase 1 results in plaque psoriasis, atopic dermatitis and skin aging.

Source: https://en.bioecon.ru/companies/rubedo-life-sciences/
Updated: 2026-07-03

- Country: United States

## Technologies

- [Geroscience & senolytics](https://en.bioecon.ru/technology/geroscience-senolytics/)